The two related basic helix loop helix genes, LYL and TAL-1 are active in hematopoietic and endothelial lineages. While Tal-1 is essential for both hematopoietic and vascular development, the role of Lyl appears to be distinct as deficient mice are viable and display modest hematopoietic defects. Here, we reveal a role for Lyl as a major regulator of adult neovascularization. Tumors implanted into Lyl-deficient mice showed higher proliferation and angiogenesis, as evidenced by enlarged lumens, reduced pericyte coverage and increased permeability, as compared to wild type littermates. Of note, Lyl-deficient tumor vessels exhibited an up-regulation of Tal-1, the VE-Cadherin target gene, as well as Angiopoietin-2, three major actors in angiogenesis. Hematopoietic reconstitution experiments demonstrated that this sustained tumor angiogenesis was of endothelial origin. Moreover, the angiogenic phenotype observed in the absence of Lyl function was not tumor-restricted as microvessels forming in Matrigel or originating from aortic explants were also more numerous and larger than their wild-type counterparts. Finally, LYL depletion in human endothelial cells revealed that LYL controls the expression of molecules involved in the stabilization of vascular structures. Together, our data show a role for LYL in the post-natal maturation of newly formed blood vessels.
Introduction
The vascular system through development and adulthood answers to injury and remodeling and is one of the key systems sustaining normal physiology. Conversely, its deregulation also underlies multiple pathologic processes such as ischemia, inflammation and tumor.
Angiogenesis normally occurs as a sequential series of morphogenetic events resulting in a functional network of vessels. Regulation of endothelial cell function in all these processes requires the integration of complex signals by the coordinated action of specific transcription factors.
LYL is a member of the large basic helix loop helix (bHLH) family, and is closely related to
TAL-1 (also called SCL).
Both LYL and TAL-1 were identified through their involvement in chromosomal rearrangements in human T cell leukemia (reviewed in 1 ) . Tal-1 deficiency causes embryonic lethality due to the absence of hematopoietic cell formation [2] [3] [4] [5] and several studies have shown that Tal-1 is also involved in the formation of the vascular system [6] [7] [8] [9] [10] .
Unlike Tal-1, Lyl is not essential for developmental processes, since homozygous disruption of Lyl activity induces only a mild hematopoietic phenotype 11 . The viable Lyl-deficient mice display a reduced number of B cells and impaired long-term hematopoietic reconstitution capacity 11 . The highly conserved bHLH motifs between TAL-1 and LYL are functionally interchangeable to restore immature hematopoiesis in Tal-1 deficient embryonic stem cells 4, 12 .
Moreover, Tal-1 and Lyl display redundant activities to maintain adult hematopoietic stem cell functions 13 . However, full length LYL cannot rescue early lethality of embryos lacking
Tal-1 4, 14 , indicating that domains other than the bHLH exert non-redundant functions. We reported that LYL but not TAL-1, interacts with p105-NFKappaB1, and that its ectopic expression in human Jurkat T cells reduces NF-KappaB1-dependent transcription 15 .
Moreover, the N-terminal domain of LYL, which completely differs from TAL-1, mediates
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A recent study conducted in mouse embryos revealed highly overlapping expression of Lyl and Tal-1 not only in hematopoietic ontogeny but also in the developing vasculature and endocardium 17 . In adults, TAL-1 expression is undetectable in quiescent endothelium, but is present in newly formed blood vessels 18, 19 , including vascular proliferations and tumor lymphatic vessels 20, 21 . We previously reported the requirement of TAL-1 for adult endothelial morphogenesis, where it activates the expression of VE-Cadherin, the major constituent of endothelial adherens junctions 22, 23 .
The expression and the role of LYL in adult endothelium are still undefined. We show here that, in contrast to TAL-1, LYL is expressed in both angiogenic and mature adult endothelium.
Loss of function reveals that LYL is not required for the morphogenetic events leading to endothelial tube formation, but for the maturation and stabilization of newly formed blood vessels in adult mice. At the molecular level, we provide evidence that LYL controls the expression of several molecules, involved in the formation and/or the tightening of endothelial adherens junctions. Together, our data suggest a model in which TAL-1 and LYL act in a coordinated manner in adult angiogenesis to control lumen formation and vessel maturation respectively.
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Materials and Methods

Cell cultures
Primary human endothelial cells (ECs) from umbilical vein (HUVECs) In vitro quiescence assay: 10 6 HUVECs were allowed to grow to confluence onto 60 mmdishes in complete EGM2 medium containing the angiogenic growth factors VEGF and bFGF. After 48 h, medium was replaced by either EGM2 complete medium, or basal EBM2 medium supplemented with 5 % FCS (angiogenic factor starvation). After an additional 24 hculture, total RNA was prepared to analyze LYL and TAL-1 mRNA expression.
In vitro tubulogenesis assays: Individual HUVECs in basal medium containing 1 % FCS were seeded into 1 % collagen matrix as described 23 , and activated by VEGF and bFGF (20 ng/ml) and PMA (80nM) to promote tubulogenesis.
siRNA transfections: Small interfering RNA (siRNA) were transfected in HUVECs as described 23 . The sequences of duplex RNAs are presented in supplemental table ST1.
Lentivirus production and endothelial cell transductions are described in supplemental data.
RNA preparation, and real-time PCR analysis
Mouse tissues or tumors were lyzed in Trizol (Invitrogen, FRANCE), snap-frozen in liquid nitrogen and kept at -80°C until used. The PureLink Micro-to-Midi Total RNA Purification System (Invitrogen, FRANCE) was used to extract total RNA from cultured cells following the manufacturer's instructions. RNA were primed with oligo(dT) and reverse transcribed 
Western blot analysis
Western blots were performed as described 25 using the following antibodies: the mouse anti-TAL-1 mAb 3BTL73 19 , a rabbit anti-β-CATENIN polyclonal antibody (SIGMA), a rabbit anti-INTEGRIN α2 polyclonal antibody (Millipore, FRANCE).
Rap1 activity assays
Rap1 activity was measured using the Rap1 activation assay kit (Millipore, France) following manufacturer's instructions. Briefly, GTP-bound Rap1 was pulled down using RalGDS-Rap binding domain fused to glutathione-S-tranferase (GST) and immobilized to glutathione agarose beads. Precipitated GTP-bound Rap1 and total Rap1 were detected by immunoblotting with a polyclonal anti-Rap1.
Animals
C57BL/6
Lyl-deficient mice (∆ Lyl /∆ Lyl ), previously described 11 , were maintained under pathogen-free conditions in our animal facility. All experiments were conducted by authorized personnel (agreement 34-308 for NP, 34-217 for VD and 34-368 for VP) and approved by the Institutional Review Board at the Animal Facility of the IGMM. Mice genotypes were determined by PCR in the presence of 1M Betain, 1.3% DMSO and 0.5 µM of each primer (supplemental Figure ST3 ).
Tumor implantation
Lewis lung carcinoma cells (2. 
Ex vivo aortic ring cultures
Mouse aortic-ring cultures were essentially prepared as reported 26 . The aortic rings were embedded in rat tail collagen gel and cultured at 37°C and 5% CO2 in MCDB131 medium with 25 mM NaHCO3 and 2% autologous serum.
Statistical analysis
Differences between experimental groups were analyzed by unpaired Student's t test. P<0.05
was considered statistically significant. 
Results
Lyl is highly expressed in endothelium-rich adult tissues
We compared Lyl and Tal-1 expression in several tissues derived from C57BL/6 adult mice.
Due to the absence of an anti-LYL antibody suitable for immunostaining or immunoblotting, this analysis was performed at the mRNA levels by quantitative RT-PCR (qRT-PCR). As expected, strong Lyl and Tal-1 expression was detected in the spleen, in keeping with the presence of numerous hematopoietic cells ( Figure 1A ). Lyl expression was observed in all other tissues tested and more particularly in endothelium-rich tissues such as aorta and lymph nodes, whereas Tal-1 mRNAs were barely detected. These data suggested that, unlike Tal-1, Lyl is active in mature quiescent endothelium.
LYL expression occurred in both angiogenic and quiescent endothelial cells
We then assessed whether LYL expression was modulated in human endothelial cells (HUVECs) according to culture conditions that recapitulate proliferation, quiescence or angiogenesis. To reproduce the quiescence of endothelium, confluent HUVECs were starved of angiogenic growth factors for 24 h, in the presence of serum (5%) to avoid apoptosis. In these conditions, ECs tightly contacted each other and stopped to proliferate. As expected, HUVECs undergoing quiescence displayed a 50% decrease in TAL-1 mRNA levels, that we previously associated with a strong reduction in TAL-1 protein levels 22 . In contrast, LYL mRNA levels were significantly increased (about 1.6-fold, Figure 1B , top).
The activation of ECs seeded within a 3D collagen matrix by VEGF, bFGF and PMA, induced angiogenic events leading to tubular structure formation 27 . As observed for TAL-1, LYL mRNA levels were always present in these angiogenic conditions, with a significant up regulation within the first 24 hours of tubulogenesis ( Figure 1B , bottom). Together these data 
Acceleration of tumor growth in Lyl-deficient mice
Homozygous genetic Lyl disruption in mice does not produce developmental abnormalities, but moderate hematopoietic defects 11, 13, 14 . Given that TAL-1 expression is limited to developing angiogenic vessels [18] [19] [20] , and given the immature features of tumor vasculature in Lyl-deficient mice (our above data), we investigated Tal-1 expression in endothelial cells of LLC tumors arising in the three groups.
For each piece of tumor tested, Tal-1 mRNA levels were expressed relative to CD31-PECAM mRNA levels used here as an endothelial-specific gene marker. There was no significant difference in CD31 mRNA expression between the three groups in agreement with similar global CD31-immunostaining of the tumors (supplemental Figure S1 ). In contrast, Tal Figure 3A ), but not of WT mice tumors in agreement with a previous study 21 . Together, these data demonstrated that Tal-1 expression was sustained in tumor endothelial cells of Lyl-deficient mice.
We previously reported that TAL-1 activates VE-cadherin expression 23 . Moreover, Angiopoietin-2 up-expression is associated with angiogenic vessels. We therefore investigated the expression at the mRNA levels of both genes in LLC tumors grown in the three genotypes ( Figure 3B ). Both VE-cadherin and Ang-2 mRNA levels showed a similar increase (about 2- Plug sections were stained with the anti-CD31 antibody to reveal blood vessel infiltration ( Figure 5B ). Plugs that displayed large vascular cavities were excluded, since they were not suitable for immunohistochemistry studies. Matrigel implants from Δ Lyl / Δ Lyl mice showed a 2-fold increase in CD31-postive vessel infiltration compared to implants from WT/ Δ Lyl mice.
Thus, Lyl-deficiency causes an increased angiogenic response in subcutaneous Matrigel implants.
For Figure 7A ). Both cell populations showed clustering of VE-Cadherin at intercellular junctions. However, in LYL-depleted cells, the staining was often discontinuous and many gaps were present between adjacent cells, as compared to the continuous VE-Cadherin staining of CTL-hTERT1 cell perimeters.
LYL-silencing reduces the expression of several molecules that contribute to maturation of endothelial adherens junctions
Given the essential role of the small GTPase Rap1 for VE-Cadherin-dependent adhesion 35 and for the stabilization of established endothelial junctions 36,37 , we investigated whether LYL influences Rap1 activity in hTERT1 cells, by a pull-down assay using a GST fusion protein of Rap1-binding domain of RalGDS. Basal levels of activated Rap1 (GTP-bound) were significantly reduced (about 40 %) in LYL-depleted cells as compared to control hTERT1 cells ( Figure 7B ). We then assessed whether LYL modulates the expression of genes encoding guanine nucleotide exchange factors (GEFs) that activate Rap1. As shown in Figure   7C , LYL-depletion in both HUVECs and hTERT1 cells caused a significant reduction in Rap-GEF1/C3G and Rap-GEF2/DOCK4 mRNA levels. In agreement with VE-Cadherin staining ( Figure 7A ), LYL-knockdown did not change VE-cadherin mRNA levels in hTERT1, and produced a 1.4-fold stimulation of VE-Cadherin mRNA levels in HUVECs ( Figure 7C ). LYLdepletion in HUVECs and in hTERT1 cells also caused a strong decrease in ITGA2 mRNA levels (about 60 %), together with a reduced INTEGRIN-α2 protein expression ( Figure 7D ), which has an important role in endothelial cell adhesion and stability 38 . Of note, LYL depletion did not change TAL-1 protein levels in both endothelial cell types Collectively, these data show that LYL depletion decreased the expression of several important mediators of AJ assembly and stabilization, without reducing the major constituent of AJs.
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From
Discussion
The objective of this study was to delineate the role of LYL in the endothelial lineage in adulthood. Loss of function experiments identified that LYL, dispensable for initiating angiogenesis, is required during the later steps of postnatal remodeling to promote maturation of newly formed blood vessels.
Whereas Lyl activity was described in developing vasculature in embryos 17 , its expression in adult endothelium was unknown. We described here that Lyl is active in all adult mice tissues tested where quiescent stabilized vasculature dominates, in contrast to Tal-1, which is only expressed in developing vessels [18] [19] [20] . In vitro experiments confirmed that LYL expression occurs in quiescent ECs, but also in activated angiogenic ECs. The mild phenotype of Lyl-deficient mice gave us the possibility to investigate the role of this transcription factor in adult angiogenesis. We found that Lyl-deficiency causes an increased angiogenic response in three different models, i. e. implanted tumors, Matrigel plug assays and aortic ring assays,. Thus, the permeable vasculature, by allowing macromolecules to extravasate into the tumor interstitium, presumably also contributes to accelerated tumor growth in Lyl-deficient mice.
Our data suggest that Lyl is required to limit the development of vascular lumen. 22 . We found a significant increase in Tal . ANG1 acts as a Tie2 agonist to promote and maintain mature blood vessels, while ANG2 acts a Tie2-antagonist, and its increased production by angiogenic ECs destabilizes vessel coverage by pericytes 43 . One possibility is that a local excess of VE- ) ; ii) two Rap1-GEFs, C3G and Dock4 that function, through activating Rap1, at different levels in network signaling cell junction maturation (reviewed in 36,37 ).
Therefore, to explain the immature and highly angiogenic phenotype of the vessels neoformed in Δ Lyl /Δ Lyl mice, we propose that a concomitant reduction of these molecules in Lyllacking ECs contributes to impaired maturation of endothelial junctions.
Our data establish that Lyl expression occurs in both angiogenic and mature vessels, suggesting that LYL participates to the continued maintenance of the quiescent vessels. Lyl is dispensable for vascular development, indicating that its loss is compensated by other functionally similar factors that contribute to angiogenesis, namely Tal-1 that is co-expressed with Lyl in the developing vasculature 17 . However, further studies are required to investigate whether Lyl-deficiency generates minor vascular anomalies in adult tissues where Tal-1 is supposed to be inactive. Finally, our findings suggest possible medical implications. Transient normalization of tumor vasculature is emerging as a therapeutic option to improve drug delivery in anti-cancer treatment 45 . A significant increase in vascular permeability is a hallmark of inflammatory diseases such as acute lung injury, sepsis or epilepsy 46,47 . Hence, strategies designed to increase LYL activity should be considered to promote or improve endothelial barrier in these pathological situations.
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Legends to the figures
shRNA CTL-treated cell ratio was arbitrarily set at 100 %. Images shown are representative of the three experiments. Vertical lines have been inserted to indicate a repositioned gel lane.
(C) HUVECs were treated with LYL or control HLA-A siRNA and total RNA were prepared 48 hours after transfection. hTERT1 cells were transduced with lentiviruses encoding either control shRNA or LYL shRNA, and puromycin-resistant cell populations were established.
mRNA levels of the indicated gene in siRNA-treated HUVEC (black bars) or in shRNA-
